SAVA vs. MREO, RAPP, DNA, TRDA, ORKA, XERS, TRML, ALT, MNMD, and STOK
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Mereo BioPharma Group (MREO), Rapport Therapeutics (RAPP), Ginkgo Bioworks (DNA), Entrada Therapeutics (TRDA), Oruka Therapeutics (ORKA), Xeris Biopharma (XERS), Tourmaline Bio (TRML), Altimmune (ALT), Mind Medicine (MindMed) (MNMD), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.
Cassava Sciences vs.
Cassava Sciences (NASDAQ:SAVA) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
Mereo BioPharma Group's return on equity of 0.00% beat Cassava Sciences' return on equity.
Cassava Sciences received 49 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 79.03% of users gave Mereo BioPharma Group an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote.
Mereo BioPharma Group has higher revenue and earnings than Cassava Sciences.
Cassava Sciences currently has a consensus price target of $111.50, suggesting a potential upside of 3,954.55%. Mereo BioPharma Group has a consensus price target of $7.83, suggesting a potential upside of 173.89%. Given Cassava Sciences' higher probable upside, equities research analysts plainly believe Cassava Sciences is more favorable than Mereo BioPharma Group.
In the previous week, Cassava Sciences had 13 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 23 mentions for Cassava Sciences and 10 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.46 beat Cassava Sciences' score of 0.01 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.
Cassava Sciences has a beta of -0.99, meaning that its stock price is 199% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.
38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 12.2% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Mereo BioPharma Group beats Cassava Sciences on 11 of the 15 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SAVA) was last updated on 1/18/2025 by MarketBeat.com Staff
Free SAVA Stock Alerts